ClinicalTrials.gg
Active, not recruitingNCT07804745Updated Sep 30, 2026

Fertility Decision and Outcomes in Young Women With Breast Cancer

An observational study in Breast Cancer - Female and Fertility, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Active, not recruiting at 3 sites in China. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational

Updated Sep 30, 2026Primary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
300
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.

Planned enrollment
172nd of 407
300 · median 240
Started
2025
with 236 others
Observational
407 of 1,928
177 open now
Primary completion
2026-09
later than 459 of 1,063 live
Registered
1,895th of 1,928
by date

Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 172nd largest by planned enrollment of the 407 observational ones that give a count, is one of 237 that started in 2025, is one of 407 observational ones, reaches primary completion later than 459 of the 1,063 other live ones, and was the 1,895th registered.

Breast Neoplasms

14,832 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

861 more — sign in →

All 866 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 40 Years · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,928 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This observational study is to learn about the fertility outcomes and decision after breast cancer diagnosis, and the current status of fertility consultation and decision support in young women diagnosed with breast cancer in China.

03

Conditions studied

  • Breast Cancer - Female
  • Fertility

Browse trials for

Keywords

  • Breast Cancer
  • Fertility
  • Pregnancy
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Sampling method
Probability sample

Study population

This study will include female patients aged 18-40 years who were diagnosed with breast cancer between January 2013 and December 2023 at one of three participating centres in China: the Second Affiliated Hospital of Zhejiang University School of Medicine, Jilin Cancer Hospital, and Hangzhou First People's Hospital.

Eligible patients must have complete medical records and no child before cancer diagnosis.

Patients with stage IV disease at diagnosis, those with pre-existing infertility factors, or those with other malignancies, will be excluded. Patients who decline to participate or cannot be contacted for follow-up will also be excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female breast cancer patients, aged 18-40 years at diagnosis.
  • Treated at the three participating hospitals between 1 January 2013 and 31 December 2023.
  • Complete clinical documentation available in the electronic medical record system.
  • Had no child before cancer diagnosis.

Exclusion criteria

Exclusion Criteria:

  • Prior reproductive compromise (surgical or diagnostic infertility or pre-existing infertility factors) before cancer diagnosis.
  • Presented with de novo stage IV () disease.
  • Had a history of other .
  • Patients who refuse to participate or cannot be contacted for follow-up.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Case Group (No childbearing after diagnosis)

    Patients diagnosed with breast cancer who had no live birth prior to diagnosis but had no live birth after diagnosis.

    Other: No intervention (observational study)

  • Control Group (Childbearing after diagnosis)

    Patients diagnosed with breast cancer who had no live birth prior to diagnosis but had at least one live birth after diagnosis.

    Other: No intervention (observational study)

Interventions

  • OtherNo intervention (observational study)

    This is an observational study. The study is based on the real-world conditions, and doesn't have any intervention.

06

What researchers measure

Primary outcomes

  1. Childbearing after breast cancer diagnosis

    The investigators will follow up with patients who had not given birth before their cancer diagnosis, to establish whether they had given birth by the end of follow-up. It will be assessed by patient self-report during follow-up and available medical records. The outcome will be recorded as a binary variable (yes/no).

    Time frame: Up to 2026

Secondary outcomes

  1. Fertility preservation measures uptake

    The investigators will calculate the proportion of patients who underwent fertility preservation procedures in cases vs. controls.

    Time frame: up to 2026

  2. Multidisciplinary collaboration involvement

    The investigators will calculate the proportion of patients with multidisciplinary team discussion or referral involving reproductive medicine, gynecology, or fertility specialists.

    Time frame: up to 2026

07

Study locations

3 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Sep 2026, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2026
First posted
Sep 4, 2026
StartActual
Oct 15, 2025
Primary completionActual
Sep 1, 2026
CompletionEst.
Oct 31, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionChildbearing after breast cancer diagnosis: how it is measured was reworded
Sep 30, 2026
Secondary outcomes
2 description edited
What changed in the outcomes
  • DescriptionFertility preservation measures uptake: how it is measured was reworded
  • DescriptionMultidisciplinary collaboration involvement: how it is measured was reworded
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionChildbearing after breast cancer diagnosis: how it is measured was reworded
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionFertility preservation measures uptake: how it is measured was reworded
    • DescriptionMultidisciplinary collaboration involvement: how it is measured was reworded
    + 1 other change: arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07804745
Collaborators
Jilin Provincial Tumor Hospital, First People's Hospital of Hangzhou
Responsible party
Sponsor
First posted
Sep 4, 2026
Start date
Oct 15, 2025
Primary completion
Sep 1, 2026
Completion
Oct 31, 2026 (estimated)
Last update
Sep 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion